Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
(PubMed) Thal LJ, Calvani M, Amato A, Carta A
In SURMOUNT-5, 751 adults with obesity but without type 2 diabetes were randomized to the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks
adults currently take a GLP-1 medication
Less common but more serious potential side effects include pancreatitis, gallbladder problems, and changes in kidney function
Liraglutide: Liraglutide holds a significant position in the Liraglutide and Semaglutide Market Size, accounting for approximately 74.3% of total consumption volume in 2024, reflecting its long-standing presence in diabetes and obesity treatment protocols
US$ 27.89
US$ 23.55
US$ 26.22
US$ 27.89
US$ 27.90
US$ 20.48
US$ 23.76
US$ 23.44
US$ 21.57
US$ 25.83
